Dr. Jorge Cortes discusses new data on bosutinib, a new tyrosine kinase inhibitor for CML.
Revumenib Plus Azacitidine/Venetoclax Appears Safe in Older NPM1/KMT2Ar AML
The VIALE-A trial showed high activity with revumenib plus azacitidine and venetoclax for patients with NPM1m/KMT2Ar AML.
Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy
Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.
Ziftomenib Earns FDA Priority Review for R/R NPM1-Mutant AML
The FDA assigned a Prescription Drug User Fee Act date of November 30, 2025, for ziftomenib in NPM1-mutant acute myeloid leukemia.
Immunotherapy Approaches in AML
Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.
Obe-Cel Receives Positive CHMP Opinion for R/R B-Cell ALL
The positive CHMP opinion is based on results from the phase 1b/2 FELIX trial evaluating obe-cel in relapsed/refractory B-cell ALL.
3 Things You Should Know About Advances in CLL Management
Care for patients with chronic lymphocytic leukemia continues to evolve via novel targeted therapies. Here are 3 things every cancer care specialist should know about treating CLL.
